 |
 |
|
|
RESÚMENES ENERO 2005 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Schizophrenia
genes, gene expression, and neuropathology: on the matter of their convergence
P J Harrison and D
R Weinberger
Molecular Psychiatry (2005) 10, 40-68
Expanding the
'central dogma': the regulatory role of nonprotein coding genes and
implications for the genetic liability to schizophrenia
D O Perkins, C
Jeffries and P Sullivan
Molecular Psychiatry (2005) 10, 69-78
Elizabeth Cantor-Graae, and Jean-Paul Selten
Am J Psychiatry 162:12-24, January 2005
Current Options
in the Management of Olanzapine-Associated Weight Gain
E Kelly Hester Margaret R Thrower
Annals of Pharmacotherapy. 4 January 2005; DOI
10.1345/aph.1D423
Pregnancy, Delivery, and Neonatal Complications in a Population Cohort of Women With Schizophrenia and Major Affective Disorders
Assen V. Jablensky, Vera Morgan, Stephen R. Zubrick, Carol Bower, and
Li-Anne Yellachich
Am J Psychiatry 162:79-91, January 2005
Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis
Karen A. Graham, Diana O. Perkins, Lloyd J. Edwards, Robert C. Barrier
Jr., Jeffrey A. Lieberman, and Joyce B. Harp
Am J Psychiatry 162:118-123, January 2005
Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard C. Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood
Dadvand, Wynn Wynn Paing, Rita A. Shaughnessy
Am J Psychiatry 162:130-136, January 2005
Martina Hummer, Peter Malik, Rudolf W. Gasser, Alex Hofer, Georg
Kemmler, Roy Cesar Moncayo Naveda, Maria A. Rettenbacher, and W. Wolfgang
Fleischhacker
Am J Psychiatry 162:162-167, January 2005
Glucose Metabolism in Patients With Schizophrenia Treated With
Atypical Antipsychotic Agents
A Frequently Sampled Intravenous Glucose Tolerance Test and
Minimal Model Analysis
David
C. Henderson, Enrico Cagliero, Paul M. Copeland, Christina P. Borba, Eden
Evins, Doug Hayden, Mary T. Weber, Ellen J. Anderson, David B. Allison, Tara B.
Daley, David Schoenfeld, Donald C. Goff
Arch Gen Psychiatry. 2005;62:19-28
Eve C. Johnstone, Klaus P. Ebmeier, Patrick Miller, David G. C. Owens,
and Stephen M. Lawrie
The British Journal of Psychiatry (2005) 186: 18-25
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia
Miranda H. Chakos, Scott A. Schobel, Hongbin Gu, Guido Gerig, Daniel
Bradford, Cecil Charles,
Jeffrey A. Lieberman
The British Journal of Psychiatry (2005) 186: 26-31
Svetlana Hakobyan,
Anna Boyajyan and Robert B. Sim
Neuroscience Letters. Volume 374, Issue 1, 1 February
2005, Pages 35-37
Mechanisms of
action of second generation antipsychotic drugs in schizophrenia: insights from
brain imaging studies
Anissa Abi-Dargham
and Marc Laruelle
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 15-27
Obstetric complications in patients
with schizophrenia and their unaffected siblings
M. Walshe, C.
McDonald, M. Taylor, J. Zhao, P. Sham, A. Grech, K. Schulze, E. Bramon and R.M.
Murray
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 28-34
Tobacco use in
schizophrenia: a study of cotinine concentrations in the saliva of patients and
controls
Jan-Erik Strand and
Henrik Nybäck
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 50-54
M.C. Mauri, C.P.C.
Steinhilber, R. Marino, E. Invernizzi, A. Fiorentini, G. Cerveri, M.L. Baldi
and F. Barale
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 55-60
Roni Shiloh,
Avraham Shapira, Oded Potchter, Haggai Hermesh, Miriam Popper and Abraham
Weizman
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 61-64
Prefrontal
cognitive deficits in patients with schizophrenia treated with atypical or
conventional antipsychotics
U. Müller, K.
Werheid, E. Hammerstein, S. Jungmann and T. Becker
European Psychiatry. Volume 20, Issue 1, January 2005,
Pages 70-73
Dopamine D3 Receptor Ser9Gly Polymorphism and Risperidone Response
Lane, Hsien-Yuan; Hsu, Shih-Kuan; Liu,
Yi-Ching; Chang, Yue-Cune; Huang, Chiung-Hsien; Chang, Wen-Ho
Journal of Clinical Psychopharmacology. 25(1):6-11,
February 2005.
Association Between Antipsychotic Treatment and Hyperlipidemia Among
California Medicaid Patients With Schizophrenia
Lambert, Bruce L.; Chang, Ken-Yu; Tafesse,
Eskinder; Carson, William
Journal of Clinical Psychopharmacology. 25(1):12-18,
February 2005.
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women
With Schizophrenia?
O'Keane, Veronica; Meaney, Anna Maria
Journal of Clinical Psychopharmacology. 25(1):26-31,
February 2005.
Adverse Cardiac Effects Associated With Clozapine
Merrill, David B; Dec, G. William; Goff, Donald C.
Journal
of Clinical Psychopharmacology. 25(1):32-41, February 2005.
The CYP2D6 Poor
Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug
Reactions and Discontinuation
Jose de Leon,
Margaret T. Susce, Run-Mei Pan, Maureen Fairchild, Walter H. Koch, and Peter J.
Wedlund
J Clin Psychiatry 2005;66:15-27
A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine: Efficacy and Safety
A. Elif Anil
Yagcioglu, Berna B. Kivircik Akdede, Tolga I. Turgut, Mevhibe Tümüklü, M. Kâzim
Yazici, Köksal Alptekin, Aygün Ertugrul, Karu Jayathilake, Ahmet Gögüs¸, Zeliha
Tunca, and Herbert Y. Meltzer
J Clin Psychiatry 2005;66:63-72
Thyroid Function in Treatment-Resistant Schizophrenia Patients Treated With Quetiapine, Risperidone, or Fluphenazine
Deanna L. Kelly,
and Robert R. Conley
J Clin Psychiatry 2005;66:80-84
John Hennen and
Ross J. Baldessarini
Schizophrenia Research. Volume 73, Issues 2-3, 1 March
2005, Pages 139-145
T.-U.W. Woo and
A.L. Crowell
Schizophrenia Research. Volume 73, Issues 2-3, 1 March
2005, Pages 193-207
Meta-analysis of
the time-course of brain volume reduction in schizophrenia: implications for
pathogenesis and early treatment
Bryan T. Woods,
Kimberley E. Ward and Edwin H. Johnson
Schizophrenia Research. Volume 73, Issues 2-3, 1 March
2005, Pages 221-228
Plasma
concentrations of estradiol in women suffering from schizophrenia treated with
conventional versus atypical antipsychotics
Niels Bergemann,
Christoph Mundt, Peter Parzer, Iris Jannakos, Ines Nagl, Birgit Salbach, Klaus
Klinga, Benno Runnebaum and Franz Resch
Schizophrenia Research. Volume 73, Issues 2-3, 1 March
2005, Pages 357-366
Slow transcranial
magnetic stimulation can rapidly reduce resistant auditory hallucinations in
schizophrenia
Emmanuel Poulet,
Jérôme Brunelin, Benoit Bediou, Rémi Bation, Louis Forgeard, Jean Dalery,
Thierry d’Amato and Mohamed Saoud
Biological Psychiatry. Volume 57, Issue 2, 15 January
2005, Pages 188-191
Acute
weight gain, gender, and therapeutic response to antipsychotics in the
treatment of patients with schizophrenia
Haya
Ascher-Svanum, Michael D Stensland, Zhongyun Zhao and Bruce J Kinon
BMC Psychiatry 2005, 5:3; 13 January 2005
A comparison of olanzapine and risperidone on the risk of psychiatric
hospitalization in the naturalistic treatment of patients with schizophrenia
Haya Ascher-Svanum,
Baojin Zhu, Douglas Faries, and Frank R Ernst
Ann Gen Hosp Psychiatry. 2004; 3: 11.
Konstantinos N
Fountoulakis, Ioannis Nimatoudis, Apostolos Iacovides, and George Kaprinis
Ann Gen Hosp Psychiatry. 2004; 3: 4.
Can J Psychiatry 2004;49:713-718
Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome
Can J Psychiatry 2004;49:753–760
Subhagata
Chattopadhyay
The Internet Journal of Mental Health. 2004. Volume 2
Number 1
Subhagata
Chattopadhyay
The Internet Journal of Mental Health. 2004. Volume 2
Number 1
Subhagata Chattopadhyay
The Internet Journal of Mental Health. 2004. Volume 2
Number 1
Kaisa Riala,
Helinä Hakko, Matti Isohanni, Anneli Pouta, and
Pirkko Räsänen
J Psychiatry Neurosci. 2005 January; 30(1):
26–32
Cognitive Improvement in Schizophrenic Patients does not
Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs
Amisulpride
Michael Wagner, Boris B Quednow,
Jens Westheide, Thomas E Schlaepfer, Wolfgang Maier and Kai-Uwe Kühn
Neuropsychopharmacology (2005) 30, 381-390
Tae Hyon Ha, Tak
Youn, Kyoo Seob Ha, Kyu Sik Rho, Jong Min Lee, In Young Kim, Sun I. Kim and Jun
Soo Kwon
Psychiatry Research: Neuroimaging. Volume 132, Issue
3, 30 December 2004, Pages 251-260
Shape changes in
prefrontal, but not parieto-occipital regions: brains of schizophrenic patients
come closer to a circle in coronal and sagittal view
Peter Falkai, Ralf
Tepest, William G. Honer, Indra Dani, Guido Ahle, Ute Pfeiffer, Kai Vogeley,
Thomas G. Schulze, Marcella Rietschel, Joachim Cordes, Helmut Schönell,
Wolfgang Gaebel, Kai-Uwe Kühn, Wolfgang Maier, Frank Träber, Wolfgang Block,
Hans H. Schild and Thomas Schneider-Axmann
Psychiatry Research: Neuroimaging. Volume 132, Issue
3, 30 December 2004, Pages 261-271
Continuing
clozapine treatment despite neutropenia
David Esposito,
Frédéric Rouillon and Frédéric Limosin
European Journal of Clinical Pharmacology 2005;Volume
60, Number 11: 759 - 764
Effect of
erythromycin on metabolism of quetiapine in Chinese suffering from
schizophrenia
Kun-Yan Li,
Xin Li, Ze-Neng Cheng, Bi-Kui Zhang, Wen-Xing Peng and
Huan-De Li
European Journal of Clinical Pharmacology 2005;Volume
60, Number 11: 791 - 795
Feature
uncertainty: a novel test to probe prefrontal dysfunction in unaffected
siblings of schizophrenia patients
Szabolcs Kéri,
Balázs Gulyás, György Benedek and Zoltán Janka
Neuroscience Letters. Volume 375, Issue 1, 25 February
2005, Pages 33-36
The prevalence
of tardive dyskinesia after a nine month naturalistic randomized trial
comparing olanzapine with conventional treatment for schizophrenia and related
disorders
Jair de Jesus
Mari, M. S. Lima, A. Niccolai Costa, N. Alexandrino,
S. Rodrigues–Filho, I. Reis de Oliveira and
G. D. Tollefson
European Archives of Psychiatry and Clinical
Neuroscience 2005; Volume 254, Number 6: 356 - 361
Electroconvulsive
therapy for the treatment of clozapine nonresponders suffering from
schizophrenia. An open label study
K. H. Kho,
B. A. Blansjaar, S. de Vries, D. Babuskova,
A. H. Zwinderman and D. H. Linszen
European Archives of Psychiatry and Clinical
Neuroscience 2005; Volume 254, Number 6: 372 - 379
Structural brain
differences in patients with schizophrenia and schizotypal disorder
demonstrated by voxel–based morphometry
Y. Kawasaki,
M. Suzuki, S. Nohara, H. Hagino, T. Takahashi,
M. Matsui, I. Yamashita, X. A. Chitnis,
P. K. McGuire, H. Seto and M. Kurachi
European Archives of Psychiatry and Clinical
Neuroscience 2005;Volume 254, Number 6: 406 - 414
Randomized double blind comparison of olanzapine vs. clozapine on
subjective well-being and clinical outcome in patients with schizophrenia
D. Naber, M. Riedel, A. Klimke, E.-U. Vorbach, M.
Lambert, K.-U. Kühn, S. Bender, B. Bandelow, W. Lemmer, S. Moritz, R. W.
Dittmann
Acta Psychiatrica Scandinavica Volume 111 Issue
2 Page 106 - February 2005
Royal Australian and New Zealand College of Psychiatrists clinical
practice guidelines for the treatment of schizophrenia and related disorders
Royal Australian and New Zealand College of
Psychiatrists
Australian and New Zealand Journal of
Psychiatry 2005;Volume: 39 Number: 1 Page: 1 - 30
Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study
J. E. Hovens, P. J. T. Dries, C. T. M. Melman, R.
J. C. Wapenaar, A. J. M. Loonen
Journal
of Psychopharmacology, Vol. 19, No. 1, 51-57 (2005)
E Kelly Hester, Margaret R Thrower
The Annals of Pharmacotherapy: Vol. 39, No. 2, pp.
302-310
Atypical
antipsychotic agents and increased risk of diabetes: class action or
differential action?
Jambur Ananth;
Smita Kolli
Expert Opinion on Drug Safety 2005, vol. 4, no. 1, pp. 55
- 68
Vasilis P. Bozikas,
Ioannis Niopas, Anna Kafantari, Feraz Imad Kanaze, Chrysi Gabrieli, Petros
Melissidis, Katerina Gamvrula, Kostas Fokas and Athanasios Karavatos
Restoration of
frontal activation during a treatment with quetiapine: an fMRI study of blunted
affect in schizophrenia
Emmanuel Stip,
Cherine Fahim, Adham Mancini-Marďe, Lahcen Ait Bentaleb, Boualem Mensour,
Adrianna Mendrek and Mario Beauregard
Schizophrenia with
prominent catatonic features (‘catatonic schizophrenia’) I. Demographic and
clinical correlates in the chronic phase
Gabor S. Ungvari,
Siu Kau Leung, Fung Shing Ng, Hung-Kin Cheung and Tony Leung
Striatal
dopaminergic D2 receptor occupancy and clinical efficacy in psychosis
exacerbation: a 123I-IBZM study with ziprasidone and haloperidol
Iluminada Corripio,
Ana M. Catafau, Víctor Perez, Dolors Puigdemont, Esther Mena, Yolanda Aguilar,
Ignasi Carrió and Enric Álvarez
Linda S. Godleski,
L. Jane Goldsmith, W. Victor R. Vieweg, Nancy Zettwoch, Dejzi Stikovac and
Susan Lewis
Double-Blind, Placebo-Controlled, Multicenter Trial of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Outpatients With Schizophrenia
J. Alexander Bodkin, Samuel G. Siris, Paul C. Bermanzohn, John Hennen,
and Jonathan O. Cole
Am
J Psychiatry 162:388-390, February 2005
Conventional
and Atypical Antipsychotics and the Risk of Hospitalization for Ventricular
Arrhythmias or Cardiac Arrest
Rosa Liperoti,
Giovanni Gambassi, Kate L. Lapane, Claire Chiang, Claudio Pedone, Vincent Mor,
Roberto Bernabei
Arch Intern Med. 2005;165:696-701
F Angelucci, S
Brenč and A A Mathé
Molecular Psychiatry (2005) 10, 345-352
Volumetric MRI measurement
of caudate nuclei in antipsychotic-naďve patients suffering from a first
episode of psychosis
Sitra
Tauscher-Wisniewski, Johannes Tauscher, Bruce K. Christensen, David J. Mikulis
and Robert B. Zipursky
Journal of Psychiatric Research. Volume 39, Issue 4,
July 2005, Pages 365-370
Cognitive
dysfunctions in medicated and unmedicated patients with recent-onset
schizophrenia
Claire Daban,
Isabelle Amado, Marie-Chantal Bourdel, Henri Loo, Jean-Pierre Olié,
Marie-France Poirier and Marie-Odile Krebs
Journal of Psychiatric Research. Volume 39, Issue 4,
July 2005, Pages 391-398
Obsessive–compulsive
disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas
and therapeutic implications
M. Poyurovsky and
L.M. Koran
Journal of Psychiatric Research. Volume 39, Issue 4,
July 2005, Pages 399-408
Anxiety disorders
in outpatients with schizophrenia: prevalence and impact on the subjective
quality of life
Raphael J. Braga,
Mauro V. Mendlowicz, Rogério P. Marrocos and Ivan L. Figueira
Journal of Psychiatric Research. Volume 39, Issue 4, July 2005, Pages 409-414
.